Skip to main content

Table 1 Sample-sets used in the Epistasis Project

From: Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease

Group Geographical Region* Subjects Numbers % women p (AD vs controls) Median age (interquartile range) p (AD vs controls)
Bonn Bonn and Mainz, Germany Clinical AD 259 61.4   71.0 (65.1–77.5)  
   Screened controls 232 56.9 0.31 67.8 (64.4–76.1) 0.11
Bristol South-West England Autopsy AD 200 45.0   80.4 (75.6–86.0)  
   Autopsy controls 57 40.4 0.55 77.9 (72.8–82.9) 0.12
Nottingham Cambridge, England Autopsy AD 104 48.1   78.7 (70.8–84.6)  
   Autopsy controls 107 34.6 0.051 72.5 (65.6–80.0) < 0.001
OPTIMA Oxford, England Autopsy AD 163 54.6   79.5 (72.4–85.2)  
   Clinical AD 87 54.0   79.1 (73.4–84.8)  
   Screened controls 261 53.6 0.93 78.9 (72.9–83.8) 0.54
Oviedo Asturias, Spain Clinical AD 202 69.8   78.4 (74.8–82.8)  
   Screened controls 131 61.8 0.15 69.7 (63.5–74.5) < 0.001
Rotterdam Rotterdam (Ommord), the Netherlands Clinical AD 391 74.9   86.6 (82.2–91.6)  
   Screened controls 5,111 57.7 < 0.001 76.9 (71.7–83.0) < 0.001
Santander Cantabria, Spain Clinical AD 351 65.0   75.5 (70.8–78.9)  
   Screened controls 396 68.9 0.27 80.9 (74.7–85.6) < 0.001
Totals   Total AD 1,757 62.4   79.0 (73.0–85.2)  
   Total controls 6,295 57.7   76.9 (71.3–83.0)  
  1. AD = Alzheimer's disease
  2. *from which the samples were drawn.
  3. Clinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]; autopsy AD cases were diagnosed as "definite" or "probable" by CERAD criteria [11]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were ≥ 60 years of age.
  4. Age at death or last examination.